期刊文献+

非小细胞肺癌细胞MRP1表达及其与耐顺铂关系的研究 被引量:4

Expression of MRP1 in human NSCLC tissues and its relationship with resistance to DDP
原文传递
导出
摘要 目的:研究多药耐药相关蛋白1(MRP1)是否在耐顺铂(DDP)的非小细胞肺癌(NSCLC)A549/DDP中高表达,探讨MRP1与NSCLC耐DDP的关系。方法:培养来源于同一母系的2株细胞系A549细胞系和A549/DDP细胞系,采用MTT法绘制A549细胞和A549/DDP细胞的生长曲线,分别计算A549细胞和A549/DDP细胞的耐药指数;应用RT-PCR检测A549细胞和A549/DDP细胞中MRP1 mRNA的表达水平。结果:A549及A549/DDP的半数抑制浓度分别为0.65μg/mL和3.7μg/mL,得出A549/DDP对DDP的耐药性是A549的5.5倍。A549/DDP中MRP1的在转录水平的表达显著高于A549中MRP1的表达,P<0.05。结论:MRP1在耐DDP的NSCLC中高表达,而在不耐DDP的NSCLC中低表达,甚至不表达,说明MRP1的高表达与肺癌耐DDP有关,为以后研究通过抑制MRP1的表达从而逆转肺癌耐DDP提供理论依据。 OBJECTIVE: To observe the expression of multidrug resistance-associated protein 1(MRP1) in the human NSCLC cell line A549 with resistance to cisplatin(A549/DDP),so as to investigate the relationship between MRP1 and the human NSCLC cell with resistance to DDP.METHODS: Cultured two cell lines of A549 and A549/DDP which were from the same uterine.The growth curves of the two cell lines were drawn and their chemoresistance indexes were measured by methyl tetrazolium(MTT) assay.The expression levels of MRP1 mRMA in the two cell lines were observed by reverse transcription polymerase chain reaction(RT-PCR).RESULTS: The chemoresistance index for A549 and A549/DDP were 0.65 μg/mL and 3.7 μg/mL,respectively.As a result,the resistance of A549/DDP to DDP was 5.5-fold greater than that of A549,and the expression of MRP1 was significantly up-regulated in A549/DDP(P0.05).CONCLUSIONS: The expression of MRP1 in A549/DDP was up-regulated,whereas was down-regulated or none in A549.It shows that the overexpression of MRP1 has relation to the human lung cell with resistance to DDP,and provides the theory basis for reversing the sensitivity of DDP by decreasing the transcription of MRP1 mRNA.
出处 《中华肿瘤防治杂志》 CAS 2011年第14期1084-1087,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 辽宁省教育厅计划编号项目(05L469)
关键词 非小细胞肺 多药耐药相关蛋白1 顺铂 多药耐药性 carcinoma non-small cell lung multidrug resistance associated protein1 cisplatin multidrug resistance
  • 相关文献

参考文献11

  • 1TanB, Piwnca- Worms D, Ratner L. Multidrug resistance trans- porters and modulation[J]. Curr Opin Oncol, 2000,12 (5) : 450- 458.
  • 2Chauney T R. Drug resistance mechanisms in acute leukemia[J]. Curr Opin Oncol,2001,13(1) :21-26.
  • 3Jiang Z, Chen B A, Xia G H, et al. The reversal effect of mag- netic Fe304 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells[J]. International Journal of Nanomedi- cine,2009,4(2) :107- 119.
  • 4Kenji N, Yukio Y, Kazuaki F, et al. Establishment and charac- terization of a cisplatin-resistant cell line, KB-R, derived from o- ral carcinoma cell line, KB[J]. Int J Oneology, 2007,30 (3) : 1325-1322.
  • 5付爽,许蕾,王笑歌.N-乙酰半胱氨酸对耐顺铂人肺腺癌细胞A549/DDP耐药逆转及其与多药耐药蛋白表达的关系[J].中华肿瘤防治杂志,2009,16(17):1298-1301. 被引量:3
  • 6Refika I P, Yang W, William T. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system[J]. Cancer Research, 2004, 64 (7) : 6214-6224.
  • 7TanB, Piwnca- Worms D, Ratner L. Muhidrug resistance trans- porters and modulation[J] . Curr OPin Oncol, 2000,12 (5) : 450-458.
  • 8Teodori E, Dei S, Martelli C, et al. The functions and structure of ABC transporters: implications for the design of new inhibi- tors of Pgp and MRP1 to control multidrug resistance (MDR) [J]. Curr Drug Targets, 2006, 7:893-909.
  • 9Berger W, Elbling L, Hauptmann E,er al. Expression of the multidrug resistance-associated protein (MRP) and chemoresis tance of human non-small-cell lung cancer cells[J]. Int J Cancer,1997,73(1):84-93.
  • 10毛晓韵,李方治,许蕾,王笑歌.基因芯片技术筛选非小细胞肺癌A549细胞顺铂耐药相关基因的研究[J].中华肿瘤防治杂志,2008,15(16):1222-1226. 被引量:4

二级参考文献14

  • 1HUANG Zhenhua & HUANG Youguo National Laboratory of Biomacromolecules, Center for Structural and Molecular Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.The relationship between MRP1 activities and its NBD conformational changes[J].Science China(Life Sciences),2004,47(5):425-433. 被引量:3
  • 2Cheng-BoHan,Xiao-YunMao,YanXin,Shao-ChengWang,Jia-MingMa,Yu-JieZhao.Quantitative analysis of tumor mitochondrial RNA using microarray[J].World Journal of Gastroenterology,2005,11(1):36-40. 被引量:4
  • 3蔡鹏,刘叙仪,韩复生,王萍.耐顺铂人肺腺癌细胞系A_(549)DDP的建立及耐药机制[J].中国肿瘤临床,1995,22(8):582-587. 被引量:29
  • 4余时沧,钱桂生,李玉英,陆卫忠,李瑾,黄桂君.线粒体靶向MPG基因重组体对人非小细胞肺癌多药耐药细胞A549/DDP增殖的抑制作用[J].癌症,2006,25(4):421-426. 被引量:1
  • 5Christiane N, Axel P, Alexandra S. Modulation of classical multidrug resistance phenotype by RNA interference [ J ]. FEBS Letters,2003,545 (2) :145 - 150.
  • 6Pakunlu RI,Wang Y,Tsao W,et al. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense : novel multicomponent delivery system [ J ]. Cancer Research, 2004, 64 (17) :6214 - 6223.
  • 7De Pauw R, van Meerbeeck JP. Neoadjuvant chemotherapy in the treatment of non small-cell lung cancer [ J ]. Curt Opin Oncol, 2007, 19(2) :92 -97.
  • 8Raez LE, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer [ J ]. Curt Opin Oncol, 2006,18(2) :156 - 161.
  • 9Stein U, Walther W. Reversal of ABC Transporter-Dependent Multidrug Resistance in Caneer:A Realistic Option? [ J ]. American J Cancer, 2006,5(5) :285 -297.
  • 10Modok S, Mellor HR, Callaghan R. Modulation of mulfidrug resistance efflux pump activity to overcome chemoresistance in cancer[ J]. Curt Opin Pharmacol, 2006, 6(4) :350 - 354.

共引文献7

同被引文献56

  • 1刘永叶,谢晓冬,刘大为,郑振东,单学健.补中益气汤改善晚期恶性肿瘤患者生活质量:48例疗效观察[J].中国临床康复,2004,8(32):7242-7243. 被引量:23
  • 2季宇彬,江蔚新,张秀娟.补中益气汤对环磷酰胺抗癌活性和毒性的影响[J].中国中药杂志,1989,14(3):48-51. 被引量:17
  • 3封颖璐,凌昌全.人参皂苷与肿瘤[J].国外医学(肿瘤学分册),2005,32(9):665-668. 被引量:20
  • 4Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP,and the lung-resistance pro- tein LRP in multiple myeloma[J]. Med Oncol, 2002,19 (2) : 87- 104.
  • 5Zhang W,Shi Y,Chen Y, et al. Enhanced antitumor efficacy by paclitaxel loaded pluronic P123/F127 mixed micelles against non- small cell lung cancer based on passive tumor targeting and mod- ulation of drug resistanee[J]. Eur J Pharm Biopharm, 2010, 75(3) :341-53.
  • 6Breedveld P, Beninen JH, Schellens JHM. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS pen- etration of anticancer drugs [J]. Trends PharmacoI Sci, 2006, 27(1) :17-24.
  • 7Loe DW, Deeley RG, Cole SP. Biology o5 the muhidrug resist ance-associated protein,MRP[J]. Eur J Cancer, 1996,32A(6) : 945-957.
  • 8Kamangar F, Dotes GM, William FA. Patterns of cancer inci dence,mortality, and prevalence across five continents:defining priorities to reduce cancer disparities in dierent geographic re- gionsotheworld[J]. J ClinOneol,2006,24(14):2137 2150.
  • 9Bunn PA Jr,Thatcher N. Systemic treatment for advanced (stage HIB/IV) non-small cell lung cancer: more treatment options; more things to consider[J]. Conclusion J 0ncol,2008,13(Suppl 1) :37-46.
  • 10O'Mahony D,Kummar S,Gutierrez ME. Non-small-cell lung cancer vaccine therapy., a concise review[J]. J Clin Oncol, 2005,23 (35) : 9022-9028.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部